Simulations Plus (NASDAQ:SLP) Issues FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 1.070-1.200 for the period, compared to the consensus EPS estimate of 1.090. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $90.4 million. Simulations Plus also updated its FY25 guidance to $1.07-1.20 EPS.

Simulations Plus Trading Up 7.8 %

Shares of NASDAQ SLP opened at $25.68 on Friday. The stock has a fifty day simple moving average of $30.03 and a 200-day simple moving average of $30.29. Simulations Plus has a twelve month low of $23.01 and a twelve month high of $51.22. The stock has a market capitalization of $515.96 million, a PE ratio of 64.20 and a beta of 0.89.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The company had revenue of $22.43 million for the quarter, compared to analyst estimates of $21.93 million. During the same period in the prior year, the firm earned $0.20 earnings per share. The business’s revenue for the quarter was up 22.5% compared to the same quarter last year. On average, equities analysts predict that Simulations Plus will post 1.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

SLP has been the subject of a number of recent research reports. KeyCorp lifted their target price on Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, January 24th. StockNews.com upgraded Simulations Plus from a “sell” rating to a “hold” rating in a research note on Friday. Finally, William Blair reissued an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $49.40.

Insider Activity at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the transaction, the director now owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 19.40% of the stock is currently owned by insiders.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.